Regenxbio resumed with an Outperform at Raymond James

Raymond James resumed coverage of Regenxbio (RGNX) with an Outperform rating and $27 price target The firm expects the launch of Elevidys and permissive regulatory path primes RGX-202 for a similar accelerated approval on biomarker results, and says the failure of Pfizer’s program leaves a larger portion of the market. While Raymond James sees a limited role for subretinal gene therapy within neovascular retinal disease, it believes Regenxbio is well ahead of competitors and has less exposure to intraocular inflammation with potentially pivotal results coming the first half of 2026.